Cancer Immunotherapy

TREATMENTS FOR CANCER THERAPY

Surgery

Radio-therapy

Chemo-therapy

Advantages of immunotherapy

Specific action

Low side effects

Independent from genetic background of tumor cells

Immune response against tumor cells

- Innate immunity
  - NK cells
  - Macrophages
  - Complement system
- Adaptive immunity
  - Cytotoxic T-lymphocytes
  - Antibodies

CANCER IMMUNOTHERAPY

1. Enhancement of patient' immune response to cancer cells

Induction of a T-response against tumor



Induction of a T-response against tumor





Induction of a T-response against tumor





Phases of adaptive immune response





Systemic immunotherapy using cytokines and growth factors

Cytokine	Reject in animal models	Clinical studies	Toxicity
IL-2	yes	Melanoma, Renal and Colon carcinoma (response rate < 15%)	Vascular permeability, Shock, edema
IFN-gamma	No	Approved for melanoma	Fever
TNF	only after local administration	Sarcoma, melanoma (in local perfusion)	Septic shock syndrome
IL-12	Variable	Melanoma	Epatic Toxicity
GM-CSF	No	Bone marrow recovery	Bone pain

Induction of a T-response against tumor



CANCER IMMUNOTHERAPY

1. Enhancement of patient' immune response to cancer cells

(VACCINATION)

Antitumoral Vaccination

Type of vaccination	Vaccine preparation	Animal models	Clinical studies
Died cancer cells	a) Tumor cells + adjuvants. b) lyseted tumor cells + adjuvants	Melanoma, Colon carcinoma. Sarcomas	Melanoma, Colon carcinoma. Melanoma
Purified tumor antigens	a) Melanoma Ags b) Heat Shock Protein	Melanoma several different models	Melanoma. Melanoma, Renal carcinoma, Sarcomas
APC-Based vaccines	a) TAA primed DC b) transfected DC (TAA-encoding vectors)	Melanoma, B linfoma, sarcoma Melanoma, Colon carcinoma	Melanoma, Non-Hodgkin linfoma, others Carcinomas



Antitumoral Vaccination

Type of vaccination	Vaccine preparation	Animal models	Clinical studies
Died cancer cells	a) Tumor cells + adjuvants. b) lyseted tumor cells + adjuvants	Melanoma, Colon carcinoma. Sarcomas	Melanoma, Colon carcinoma. Melanoma
Purified tumor antigens	a) Melanoma Ags b) Heat Shock Protein	Melanoma several different models	Melanoma. Melanoma, Renal carcinoma, Sarcomas
APC-Based vaccines	a) TAA primed DC b) transfected DC (TAA-encoding vectors)	Melanoma, B linfoma, sarcoma Melanoma, Colon carcinoma	Melanoma, Non-Hodgkin linfoma, others Carcinomas
Vaccination enhanced by cytokines or co-stimulatory molecules	a) Transfected tumor cells (vector encoding cytokines or B7) b) Transfected tumor cells (vector encoding cytokines or B7) and pulsed with TAA	Renal and pulmonary Carcinomas, Sarcomas, B-leukemies	Melanoma, sarcomas Melanoma, Renal carcinoma



Induction of a T-response against tumor



Phagocytosis of apoptotic cells

Antitumoral Vaccination

Type of vaccination	Vaccine preparation	Animal models	Clinical studies
Died cancer cells	a) Tumor cells + adjuvants. b) lyseted tumor cells + adjuvants	Melanoma, Colon carcinoma. Sarcomas	Melanoma, Colon carcinoma. Melanoma
Purified tumor antigens	a) Melanoma Ags b) Heat Shock Protein	Melanoma several different models	Melanoma. Melanoma, Renal carcinoma, Sarcomas
APC-Based vaccines	a) TAA primed DC b) transfected DC (TAA-encoding vectors)	Melanoma, B linfoma, sarcoma Melanoma, Colon carcinoma	Melanoma, Non-Hodgkin linfoma, others Carcinomas
Vaccination enhanced by cytokines of co-stimulatory molecules	a) Transfected tumor cells (vector encoding cytokines or B7) b) Transfected tumor cells (vector encoding cytokines or B7) and pulsed with TAA	Renal and pulmonary Carcinomas, Sarcomas, B-leukemies	Melanoma, sarcomas Melanoma, Renal carcinoma
DNA vaccination	Vectors encoding TAA	Melanoma	Melanoma
Viral vectors	Adenovirus encodingTAA + cytokines	Melanoma, sarcomas	Melanoma

CANCER IMMUNOTHERAPY

1. Enhancement of patient' immune response to cancer cells

2. Passive immunotherapy using T lymphocytes






A
Generation of tumor-specific CTL clones
Melanoma
Purify mononuclear cells from tumor site
Surgically resect tumor
Patient's mononuclear cells
Tumor cells
Melanoma cell line
Coculture mononuclear cells and melanoma cells
Isolate and clone activated CD8+ CTLs



CANCER IMMUNOTHERAPY

1. Enhancement of patient' immune response to cancer cells

2. Passive immunotherapy using T lymphocytes

3. **Passive immunotherapy using antibodies**

Antibodies


Antigen binding sites
Variable region on heavy chain
Light chain
Disulfide bridges
Variable region on light chain
Constant region on light chain
Heavy chain
Constant region on heavy chain


target binding
V_H
V_L
C_{H1}
C_L
C_{H2}
C_{H3}
effector functions

isotiopo	Sottotipo	Concentrazione nel siero (mg/ml)	Emivita nel siero (giorni)	Forma secreta
IgA	1,2	3,5	6	
IgD	-	-	3	-
IgE	-	0,05	2	
IgG	1-4	13,5	23	
IgM	-	1,5	5	

Antibody Isotope	Isotype-specific effector functions
IgG	- Opsonization of antigens for phagocytosis by macrophages and neutrophils - Activation of the classical pathway of complement - Antibody-dependent cell-mediated cytotoxicity mediated by natural killer cells - Neonatal immunity: transfer of maternal antibody across the placenta and gut - Feedback inhibition of B cell activation
IgM	- Activation of the classical pathway of complement - Antigen receptor of naive B lymphocytes
IgA	- Mucosal immunity: secretion of IgA into the lumens of the gastrointestinal and respiratory tracts - Activation of complement by the lectin pathway or by the alternative pathway
IgE	Mast cell degranulation (immediate hypersensitivity reactions)
IgD	Antigen receptor of naive B lymphocytes

FcR	Affinity for immunoglobulin	Cell Distribution	Function
Fc γ RI (CD64)	High (Kd ~ 10^{-9} M) binds IgG1 and IgG3	Macrophages, neutrophils; also eosinophils	Phagocytosis, activation of phagocytes
Fc γ RIIA (CD32)	Low (Kd > 10^{-7} M)	Macrophages, neutrophils; eosinophils, platelets	Phagocytosis; cell activation (inefficient)
Fc γ RIIB (CD32)	Low (Kd > 10^{-7} M)	B lymphocytes, dendritic cells, macrophages	Feedback inhibition of B cells, macrophages, dendritic cells
Fc γ RIIIA (CD16)	Low (Kd > 10^{-6} M)	NK cells	Antibody-dependent cell-mediated cytotoxicity
Fc γ RIIIB (CD16)	Low (Kd > 10^{-6} M) GPI-linked protein	Neutrophils, other cells	Phagocytosis (inefficient)
Fc ε RI	High (Kd > 10^{-10} M) binds monomeric IgE	Mast cells, basophils, eosinophils	Cell activation (degranulation)
Fc ε RII (CD23)	Low (Kd > 10^{-7} M)	B lymphocytes, eosinophils, Langerhans cells	Unknown
Fc α R (CD89)	Low (Kd > 10^{-6}M)	Neutrophils, eosinophils, monocytes	Cell activation?

Mechanisms of action of anti-tumor recombinant antibodies

CITOTOSSICITA' CELLULARE ANTICORPO DIPENDENTE (ADCC)	Mediata in particolare dalle cellule NK, che tramite il recettore FcgRIII riconosce la porzione Fc dell'anticorpo. Liberazione del contenuto dei granuli citoplasmatici (perforine, granzimi).
OPSONIZZAZIONE E FAGOCITOSI	Gli anticorpi rivestono la cellula tumorale e ne favoriscono l'internalizzazione da parte dei fagociti che riconoscono la porzione Fc mediante i recettori per Fc.
APOPTOSI	Da aggregazione dell'antigene sulla superficie cellulare.
ATTIVAZIONE DELLA VIA CLASSICA DEL COMPLEMENTO	Legame di C1q all'Fc dell'anticorpo; lisi cellulare (CDC); i prodotti generati dall'attivazione del complemento (anafilotossine e opsonine) inducono flogosi e promuovono la fagocitosi.

Characteristics of recombinant antibodies

- Specificity
- Activation of the immune system
- Biodistribution/half life in the cisulation

Antibody engineering

- Transgenic mici
- Phage display library



Immunogen; short halflife; mouse Fc region induces a low activation of human immune funtions

Less immunogenic; long half-life in the serum; guarantee the activation of Fc-mediated effector functions

Antibody fragments





Antibody fragments

IgG
(150 kDa)

Fab
(50 kDa)

$F(ab')_2$
(50 kDa)

Monospecific
Fab_2 (50 kDa)

Bispecific Fab_2
(50 kDa)

Trispecific
Fab_3 (150 kDa)

Monovalent
IgG (75kDa)

scFv
(25 kDa)

Bispecific
Diabody
(50 kDa)

Trispecific
Triabody
(75 kDa)

scFv-Fc
(100 kDa)

Minibody
(75 kDa)

IgNAR
(175 kDa)

V-NAR
(15 kDa)

hcIgG
(75 kDa)

VhH
(15 kDa)

Market of anti-tumor antibodies

Generic name (trade name; sponsoring companies)	Target	Antibody Format	Cancer Indication	Refs
Unconjugated antibodies				
Rituximab (Rituxan/Mabthera; Genentech/Roche/Biogen Idec)	CD20	Chimeric IgG1	Non-Hodgkin lymphoma	74,105
Trastuzumab (Herceptin; Genentech/ Roche)	HER2	Humanized IgG1	Breast cancer	19,72
Alemtuzumab (Campath/ MabCampath; Genzyme/Bayer)	CD52	Humanized IgG1	Chronic lymphocytic leukaemia	58
Cetuximab (Erbitux; ImClone Systems/Bristol–Myers Squibb)	EGFR	Chimeric IgG1	Colorectal cancer	13,106
Bevacizumab (Avastin; Genentech)	VEGFA	Humanized IgG1	Colorectal, breast and lung cancer	71, 107,108
Panitumumab (Vectibix; Amgen)	EGFR	Human IgG2	Colorectal cancer	109
Ofatumumab (Arzerra; Genmab/ GlaxoSmithKline)	CD20	Human IgG1	Chronic lymphocytic leuakemia	110
Immunoconjugates				
Gemtuzumab ozogamicin (Mylotarg; Pfizer)	CD33	Humanized IgG4	Acute myelogenous leukaemia	111
^{90}Y-Ibritumomab tiuxetan (Zevalin; Biogen Idec)	CD20	Mouse	Lymphoma	112
Tositumomab and ^{131}I-tositumomab (Bexxar; GlaxoSmithKline)	CD20	Mouse	Lymphoma	113

EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; VEGF, vascular endothelial growth factor.

Weiner et al, Nature Review, 2010

Therapeutic antibodies in oncology



9762 Studies found for: **antibody | Cancer**

Also searched for **Neoplasm**, **Tumor**, **Immunoglobulins** and more. See Search Details

List | By Topic | On Map | Search Details

Hide Filters

Download | Subscribe to RSS

Filters

Apply | Clear

Status

Recruitment :

- Not yet recruiting
- Recruiting
- Enrolling by invitation
- Active, not recruiting
- Suspended
- Terminated
- Completed
- Withdrawn
- Unknown status†

Showing: 1-10 of **9,762** studies 10 studies per page

Show/Hide Columns

Row	Saved	Status	Study Title	Conditions	Interventions	Locations
1		Completed	Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal **Antibody** for Patients With Advanced Breast **Cancer**	• Breast **Cancer**	• Biological: humanized anti-PD-1 monoclonal **antibody** toripalimab	• Gastrointestinal Oncology Department, Affiliated Cancer Center of Academy of Military Medical Sciences Beijing, Beijing, China
2		Recruiting	Anti-PD-1 **Antibody** Combined With Anlotinib in the Treatment of Endometrial **Cancer**	• Endometrial **Cancer**	• Drug: anlotinib and anti PD-1 **antibody**	• Sun Yat-sen University Cancer Centre Guangzhou, Guangdong, China
3		Recruiting	Combination of Radiation Therapy and Anti-PD-1 **Antibody** in Treating Patients With Pancreatic **Cancer**	• Pancreatic **Cancer**	• Radiation: Radiation • Drug: Anti-PD-1 **Antibody**	• Hangzhou Cancer Hospital Hangzhou, Zhejiang, China
4		Unknown †	Stereotactic Body Radiation Therapy Combined With Anti-PD-1 **Antibody** in Metastatic Triple Negative Breast **Cancer**	• Metastatic Breast **Cancer**	• Radiation: stereotactic body radiation therapy	• Fudan University Shanghai Cancer Center Shanghai, China
5		Unknown †	A Study of Combination of Anti-PD1 **Antibody**-activated TILs and Chemotherapy in Colorectal **Cancer**	• Colorectal **Cancer** Stage III	• Biological: anti-PD-1 **antibody**-activated TILs	• Sun Yat-Sen University, Cancer Center Guangzhou, Guangdong, China

Antigeni associati al Linfoma contro cui sono stati isolati anticorpi

CD19	Hekman, Cancer Immunol Immunother, 1991
CD20	Davis, Clin Cancer Res, 1999
CD22	Leonard, J Clin Oncol, 2003
CD52	Dyer, Blood, 1989
Idiotipo	Kwak, N England J Med, 1992

CD20

- Fosfoproteina transmembrana
- Dominio unico extracellulare
- Ligando naturale non identificato
- Funzione biologica ipotizzata: canale ionico al Ca^{++}
- Resistente ad internalizzazione e secrezione



Rituximab (IDEC-C2B8; Rituxan®; MabThera®)

Proprietà molecolari



Anticorpo monoclonale anti CD20

Anticorpo chimerico:

Sito di legame antigenico di origine murina fuso a regioni costanti della catena pesante (H) umana IgG1k e della catena leggera (L) umana k.

Effetto del Rituximab in un modello in vivo di linfoma non-Hodgkin's



C57BL/6

$C1q^{-/-}$ (C57BL/6)



Di Gaetano et al. J. Immunol, 2003

Associazione Rituximab-chemioterapia

Rituximab + Fludarabine	Di Gaetano, Br J Haematol, 2001
Rituximab + Fludarabine	Byrd, Blood, 2003
Rituximab + CHOP (insieme o come mantenimento)	Habermann, Blood, 2004
Rituximab + FND	McLaughlin, Ann Oncol, 2005

VALUTAZIONE FARMACOECONOMICA

	CHOP	R-CHOP	Differenza
Indice di Risposta	62,1%	75,4%	13,3%
Sopravvivenza in anni			
Libera da malattia	2,93	4,71	1,77
Complessiva	5,25	6,43	1,19
Post-progressione	2,10	1,54	-0,57
Sopravvivenza complessiva media	4,85	5,93	1,08
QALYs	3,08	4,23	1,15
Costi Terapia			
Rituximab		€13.631	€13.631
CHOP	€977	€1.033*	€56
Follow-up	€ 3.612	€4.764*	€1.151
Totale	€ 4.589	€19.427	€14.838
Costo/Eff			
Per Life Years guadagnata			€13.732
Per QALY guadagnata			€12.879

Costi dell'immunoterapia con Rituximab

- Un ciclo di terapia con Rituximab costa circa 15.000 euro a paziente con linfoma Non-Hodgkin
- In Italia si spendono all'anno 200 milioni di euro solo per Rituximab

Q J Med 2008; **101**:737–740
doi:10.1093/qjmed/hcn085 Advance Access published on 23 July 2008

Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL

A. KLEPFISH[1], E.A. RACHMILEWITZ[1], I. KOTSIANIDIS[2], P. PATCHENKO[1] and A. SCHATTNER[3]

From the [1]Blood Bank and Haematology Department, E. Wolfson Medical Centre, Holon, [2]The Haematology Department, Democritus University of Thrace School of Medicine, Alexandroupolis, Greece and [3]The Hebrew University Hadassah Medical School, Jerusalem, Israel

Received 6 May 2008 and in revised form 16 June 2008

Summary

Background: Many patients with chronic lymphocytic leukaemia (CLL) develop progressive, treatment-resistant disease. Rituximab (RTX), a monoclonal antibody targeting CD20 on B lymphocytes and widely used in other indolent B cell neoplasms is less efficacious in CLL, possibly due to associated complement deficiencies.

Objective: To examine in open trial whether providing complement by concurrent administration of fresh frozen plasma (FFP) will enhance the effect of RTX in CLL.

Setting: Outpatient haematology clinics in Israel and Greece.

Patients: Five patients with severe treatment-resistant CLL. All had been previously treated with fludarabine and three also failed treatment with RTX.

Intervention: Two units of FFP followed with RTX 375 mg/m^2 as a single agent, repeated every 1–2 weeks, as needed.

Results: A rapid and dramatic clinical and laboratory response was achieved in all patients. Lymphocyte counts dropped markedly followed by shrinkage of lymph nodes and spleen and improvement of the anaemia and thrombocytopenia. This could be maintained over 8 months (median) with additional cycles if necessary. Treatment was well tolerated in all cases.

Conclusion: Adding FFP to RTX may provide a useful therapeutic option in patients with advanced CLL resistant to treatment.